Positions

Overview

  • Introduction:

    Dr. Lin completed his Sc.B. in Biochemistry with honors at Brown University before going on to train in the NIH-supported Medical Scientist Training Program (MSTP) at the University of Alabama at Birmingham (UAB), receiving both an MD and a PhD in Cell Biology. After completing his training, he joined the Department of Medicine at UAB as an Instructor in the Division of Hematology and Oncology with a clinical focus in lung cancer and sarcoma and a research focus in precision oncology. He is the Associate Director of the UAB Molecular Tumor Board and also serves on the UAB MSTP Advisory Committee.

    Clinical Interests:

    Lung cancer and sarcoma

    Research Interests:

    His dissertation research in the lab of Fang-Tsyr (Fannie) Lin centered around thyroid hormone receptor interacting protein 6 (TRIP6), an adaptor protein that is upregulated in a number of malignancies, including ovarian cancer and glioblastoma. His work illustrated how TRIP6 specifically regulates p27KIP1, a CDK inhibitor that is an important prognostic determinant in cancer. He went on to complete his residency in Internal Medicine and fellowship in Hematology and Oncology as part of the ABIM Research Pathway at UAB. During this time, he did his postdoctoral fellowship in the lab of Lalita Shevde-Samant, where his research focused on the role of the Hedgehog pathway in regulating DNA repair, particularly the role of GLI1 in enabling the repair of double strand breaks in ribosomal DNA (rDNA). He currently has a research focus in precision oncology.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Hedgehog signaling enables repair of ribosomal DNA double-strand breaksNucleic Acids Research.  48:10342-10352. 2020
    2019 The pros and cons of incorporating transcriptomics in the age of precision oncologyJournal of the National Cancer Institute.  111:1016-1022. 2019
    2018 First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibitionJournal of the National Comprehensive Cancer Network : JNCCN.  16:1166-1170. 2018
    2017 Developing Cures: Targeting Ontogenesis in CancerTrends in Cancer.  3:126-136. 2017
    2016 TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activationCell Discovery.  2. 2016
    2013 Trip6 regulates p27KIP1 to promote tumorigenesisMolecular and Cellular Biology.  33:1394-1409. 2013
    2011 TRIP6: An adaptor protein that regulates cell motility, antiapoptotic signaling and transcriptional activityCellular Signalling.  23:1691-1697. 2011
    2010 The adaptor protein TRIP6 antagonizes fas-induced apoptosis but promotes its effect on cell migrationMolecular and Cellular Biology.  30:5582-5596. 2010

    Chapter

    Year Title Altmetric
    2018 Hedgehog Signaling in Carcinogenesis.  297-304. 2018

    Principal Investigator On

  • Private Grant  awarded by Genentech
  • Investigator On

    Full Name

  • Victor Lin